U.S. markets closed

Kura Oncology, Inc. (KURA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
21.31-0.28 (-1.30%)
At close: 04:00PM EST
21.73 +0.42 (+1.97%)
After hours: 04:34PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Symmetrical Continuation Triangle (Bullish)

Symmetrical Continuation Triangle (Bullish)

Previous Close21.59
Bid17.00 x 1100
Ask22.60 x 900
Day's Range21.08 - 21.77
52 Week Range7.41 - 22.92
Avg. Volume1,605,210
Market Cap1.623B
Beta (5Y Monthly)0.86
PE Ratio (TTM)N/A
EPS (TTM)-2.08
Earnings DateMay 08, 2024 - May 13, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for KURA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Kura Oncology, Inc.
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
  • GlobeNewswire

    Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on March 1, 2024, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 93,000 shares of common stock to two (2) new employees under

  • Insider Monkey

    Kura Oncology, Inc. (NASDAQ:KURA) Q4 2023 Earnings Call Transcript

    Kura Oncology, Inc. (NASDAQ:KURA) Q4 2023 Earnings Call Transcript February 27, 2024 Kura Oncology, Inc. beats earnings expectations. Reported EPS is $-0.55, expectations were $-0.56. Kura Oncology, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, ladies and […]

  • Thomson Reuters StreetEvents

    Q4 2023 Kura Oncology Inc Earnings Call

    Q4 2023 Kura Oncology Inc Earnings Call